However, a clinical trial combining ASP2215 and erlotinib in EGFR-positive NSCLC patients following EGFR inhibitor treatment (NCT02495233) was halted due to significant serious adverse effects associated with the combination medication. Here, EGFR is linked to non-small cell lung carcinoma.